Related Experiment Video
Updated: Apr 23, 2026
A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
Published on: November 7, 2025
[Bone-targeted treatment in prostate cancer]
Lajos Géczi1, István Sinkovics2
1Kemoterápia C Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary. gelajos@oncol.hu.
Abstract:
Prostate cancer is one of the most common cancers in men. In case of metastatic disease, bone manifestation is presented in 85-90% of the patients. The new targeted treatments are the denosumab RANK-ligand monoclonal antibody and Ra-223-chloride radioisotope therapy. This paper summarizes the treatment possibilities of bone metastasis and presents the results of phase III trials of denosumab and Ra-223-chloride. The upcoming change in financial support underlines the actuality of this paper.
Insights
New treatments for prostate cancer bone metastasis, denosumab and Ra-223-chloride, show promise. This paper reviews their efficacy and clinical trial results for managing advanced prostate cancer bone spread.
Area of Science:
- Oncology
- Radiochemistry
- Pharmacology
Background:
- Prostate cancer is a leading cause of cancer in men.
- Bone metastasis occurs in 85-90% of advanced prostate cancer patients.
- Effective management of bone metastasis is crucial for patient outcomes.
Purpose of the Study:
- To summarize current treatment options for prostate cancer bone metastasis.
- To present and analyze results from Phase III clinical trials of denosumab and Ra-223-chloride.
- To highlight the clinical relevance of these targeted therapies.
Main Methods:
- Review of Phase III clinical trial data for denosumab.
- Review of Phase III clinical trial data for Ra-223-chloride.
- Comparative analysis of treatment efficacy and safety profiles.
Main Results:
- Denosumab (RANK-ligand monoclonal antibody) demonstrated significant benefits in preventing skeletal-related events.
- Ra-223-chloride (radioisotope therapy) showed improved overall survival in metastatic castration-resistant prostate cancer patients with bone metastases.
- Both agents represent advancements in targeted therapy for bone manifestations.
Conclusions:
- Denosumab and Ra-223-chloride are effective targeted treatments for prostate cancer bone metastasis.
- These therapies offer improved outcomes and quality of life for affected patients.
- The findings support the use of these agents in clinical practice, especially considering financial support changes.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies